↓ Skip to main content

American Association for Cancer Research

Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery

Overview of attention for article published in Molecular Cancer Therapeutics, August 2006
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (69th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
2 X users
patent
19 patents

Citations

dimensions_citation
671 Dimensions

Readers on

mendeley
753 Mendeley
citeulike
3 CiteULike
Title
Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery
Published in
Molecular Cancer Therapeutics, August 2006
DOI 10.1158/1535-7163.mct-06-0141
Pubmed ID
Authors

Rajni Sinha, Gloria J. Kim, Shuming Nie, Dong M. Shin

Abstract

Nanotechnology refers to the interactions of cellular and molecular components and engineered materials-typically, clusters of atoms, molecules, and molecular fragments into incredibly small particles-between 1 and 100 nm. Nanometer-sized particles have novel optical, electronic, and structural properties that are not available either in individual molecules or bulk solids. The concept of nanoscale devices has led to the development of biodegradable self-assembled nanoparticles, which are being engineered for the targeted delivery of anticancer drugs and imaging contrast agents. Nanoconstructs such as these should serve as customizable, targeted drug delivery vehicles capable of ferrying large doses of chemotherapeutic agents or therapeutic genes into malignant cells while sparing healthy cells. Such "smart" multifunctional nanodevices hold out the possibility of radically changing the practice of oncology, allowing easy detection and then followed by effective targeted therapeutics at the earliest stages of the disease. In this article, we briefly discuss the use of bioconjugated nanoparticles for the delivery and targeting of anticancer drugs.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 753 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 5 <1%
India 4 <1%
Brazil 4 <1%
Iran, Islamic Republic of 3 <1%
Portugal 2 <1%
Spain 2 <1%
Germany 2 <1%
Egypt 2 <1%
Netherlands 1 <1%
Other 7 <1%
Unknown 721 96%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 164 22%
Student > Master 150 20%
Student > Bachelor 85 11%
Researcher 75 10%
Student > Postgraduate 43 6%
Other 101 13%
Unknown 135 18%
Readers by discipline Count As %
Agricultural and Biological Sciences 143 19%
Chemistry 116 15%
Biochemistry, Genetics and Molecular Biology 76 10%
Pharmacology, Toxicology and Pharmaceutical Science 70 9%
Engineering 59 8%
Other 135 18%
Unknown 154 20%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 October 2023.
All research outputs
#6,228,314
of 23,056,273 outputs
Outputs from Molecular Cancer Therapeutics
#1,378
of 3,876 outputs
Outputs of similar age
#20,352
of 67,286 outputs
Outputs of similar age from Molecular Cancer Therapeutics
#28
of 52 outputs
Altmetric has tracked 23,056,273 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 3,876 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one has gotten more attention than average, scoring higher than 64% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 67,286 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.
We're also able to compare this research output to 52 others from the same source and published within six weeks on either side of this one. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.